Body Mass Index Increase, Serum Leptin, Adiponectin, Neuropeptide Y and Lipid Levels during Treatment with Olanzapine and Haloperidol

Abstract

Introduction

Body mass index (BMI) increase is an undesired effect associated with antipsychotics, and crucial for patients’ global health and treatment compliance. We aimed to investigate the relation between BMI during olanzapine or haloperidol treatments and leptin, neuropeptide Y (NPY), adiponectin and lipid serum levels.

Methods

In this 9-month, randomized and naturalist study, 34 male patients, 18 on olanzapine and 16 on haloperidol group were enrolled, all were under monotherapy. Patient outcome was evaluated with positive and negative syndrome scale (PANSS) at every 3-month period. In each visit, BMI, leptin, NPY, lipid, olanzapine or haloperidol levels were also monitored.

Results and Discussion

Leptin levels positively correlated with BMI in olanzapine (r=0.64, p<0.001) and haloperidol (r=0.73, p<0.001) groups; only in olanzapine patients, the former also correlated with PANSS score (r=0.54, p<0.05). NPY levels negatively correlated with olanzapine levels (r=− 0.65, p<0.01). Adiponectin levels had not significantly varied.

Conclusion

Antipsychotics probably interfere on leptin and NPY signalling ways and disturb these hormones in eating behaviour control.

Key words

antipsychotic drugs - adverse effects - leptin - neuropeptide Y - adiponectin - body mass index

• References

• 1 Bernstein JG. Induction of obesity by psychotropic drugs. Ann N Y Acad Sci 1987; 499: 203-215
• 2 Baptista T, Lacruz A, de Mendonza S et al. Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. Pharmacopsychiatry 2000; 33: 81-88
• 3 Parsons B, Allison DB, Loebel A et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009; 110: 103-110
• 4 Wirshing DA, Wirshing WC, Kysar L et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358-363
• 5 Kraus T, Haack M, Schuld A et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry 1999; 156: 312-314
• 6 Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms. Pharmacol Ther 2010; 125: 169-179
• 7 Valassi E, Scacchi M, Cavagnini F. Neuroendocrine control of food intake. Nutr Metab Cardiovasc Dis 2008; 18: 158-168
• 8 Jin H, Meyer JM, Mudaliar S et al. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res 2008; 100: 70-85
• 9 De Leon J, Susce MT, Jonhson M et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res 2007; 92: 95-102
• 10 Mukherjee S, Decina P, Bocola V et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996; 37: 68-73
• 11 Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4^th edition Washington, DC: American Psychiatric Press; 1994
• 12 Kay SR, Opler LA, Lindenmayer JP. The positive and negative syndrome scale (PANSS): rationale and standardization. Br J Psychiatry 1989; 155: 59-65
• 13 Olesen OV, Linnet K. Determination of olanzapine in serum by high-performance liquid chromatography using ultraviolet detection considering the easy oxidability of the compound and the presence of other psychotropic drugs. J Chromatogr B Biomed Sci Appl 1998; 714: 309-315
• 14 Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000; 61: 742-749
• 15 Morimoto T, Yamamoto Y, Mobarakeh JI et al. Involvement of the histaminergic system in leptin-induced suppression of food intake. Physiol Behav 1999; 67: 679-683
• 16 Dryden S, Brown M, King P et al. Decreased plasma leptin levels in lean and obese Zucker rats after treatment with the serotonin reuptake inhibitor fluoxetine. Horm Metab Res 1999; 31: 363-366
• 17 Meguid MM, Fetssov SO, Varma M et al. Hypothalamic dopamine and serotonin in the regulation of food intake. Nutrition 2000; 16: 843-857
• 18 Leibowitz SF, Alexander JT. Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol Psychiatry 1998; 44: 851-864
• 19 Marquina D, Peña R, Fernández E et al. Int Clin Psychopharmacol 2011; 26: 169-172
• 20 Näslund E, Hellström PM. Appetite signaling: From gut peptides and enteric nerves to brain. Physiol Behav 2007; 92: 256-262
• 21 Considine RV, Sinha MK, Heiman ML et al. Serum immunoreactive-leptin concentrations in normal weight and obese humans. N Engl J Med 1996; 334: 292-295
• 22 Foutaine RJ, Taylor AE, Mancuso JP et al. Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity 2010; 18: 1646-1651
• 23 Kluge M, Schuld A, Schacht A et al. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. Psychoneuroendocrino 2009; 34: 118-128
• 24 Esen-Danaci A, Sarandõi A, Tanellu F et al. Effects of second generation antipsychotics on leptin and ghrelin. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1434-1438
• 25 Kim B, Sohn J, Park C et al. Body weight and plasma levels of ghrelin and leptin during treatment with olanzapine. J Korean Med Sci 2008; 23: 685-690
• 26 Chaggar PS, Shaw SM, Williams SG. Effect of antipsychotic medications on glucose and lipid levels. J Clin Pharmacol 2010; doi:
• 27 Monteleone P, Martiadis V, Maj M. Management of schizophrenia with obesity, metabolic, and endocrinological disorders. Psychiatr Clin North Am 2009; 32: 775-794
• 28 Kolakowska T, Gadhvi H, Molyneux S. An open clinical trial of fenfluramine in chronic schizophrenia: a pilot study. Int J Clin Psychopharmacol 1987; 2: 83-88
• 29 Knox JM. A study of weight reducing diets in psychiatric in-patients. Br J Psychiatry 1980; 136: 287-289
• 30 Rotatori AF, Fox R, Wicks A. Weight loss with psychiatric residents in a behavioral self-control program. Psychol Rep 1980; 6: 483-486
• 31 Ugur T, Bartels M, Kis B et al. Psychosis following anti-obesity treatment with rimonabant. Obes Facts 2008; 1: 103-105